Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Licenses Nucleic Acid Patents to NimbleGen

This article has been updated from a previous version, which incorrectly reported that NimbleGen had licensed and planned to sell Affymetrix's microarrays.
 
NEW YORK (GenomeWeb News) – Affymetrix has granted NimbleGen a license to patents covering the manufacture, use, and sale of nucleic acid microarrays, the companies said today.
 
"This license is a major milestone in NimbleGen's evolution as a company, and part of a fundamental expansion of our commercial strategy," said Stan Rose, president and CEO of NimbleGen, in statement. "Our intent is to expand dramatically the ability of scientists to access NimbleGen products and services."
 
Financial details were not disclosed.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.